Glibomet v lechenii sakharnogo diabeta 2 tipa
https://doi.org/10.14341/2072-0351-5799
Abstract
About the Authors
Alexander Sergeevich AmetovI V Kozedubova
References
1. Startton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
2. Fore W.W. Noninsulin-dependent diabetes mellitus. The prevention of complications. Med Clin North Am. 1995 Mar;79(2):287-98.
3. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Tenyear cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993 Nov;36(11):1175-84
4. Garber A.J. Vascular disease and lipids in diabetes. Med Clin North Am. 1998 Jul;82(4):931-48.
5. Yoshino G.; Hirano T.; Kazumi T. Dyslipidemia in diabetes mellitus. Diabetes Res Clin Pract. 1996 Jun;33(1):1-14
6. Дедов И.И., Демидова И.Ю. Основные принципы терапии сахарного диабета 2 типа // Сахарный диабет. 1999. № 1. с. 23-27.
7. Campbell IW. Need for intensive early glycaemia control in patients. with type 2 diabetes. Br J Cardiol 2000; 7: 625-631.
8. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.. JAMA. 1999 Jun 2;281(21):2005-12
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21
10. Демидова И.Ю. Применение пероральных сахароснижающих средств в лечении инсулиннезависимого сахарного диабета. Русский медицинский журнал 1998. т.6, № 12. с 774-778.
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53.
12. Garber A, Marre M, Blonde L, Allavoine T, Howlett H, Lehert P, Cornes M. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. Diabetes Obes Metab. 2003 May;5(3):171-9.
13. Анциферов М.Б., Майоров А.Ю., Дорофеева Л.Г. Опыт использования комбинированного сахароснижающего препарата глибомет (глибенкламид + метформин) в практике лечения сахарного диабета типа 2. Фарматека № 3 - 2006, стр.68-72.
Review
For citations:
Ametov A.S., Kozedubova I.V. Glibomet v lechenii sakharnogo diabeta 2 tipa. Diabetes mellitus. 2007;10(2):63-66. https://doi.org/10.14341/2072-0351-5799
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
